Celltrion’s Remsima wins U.S. original drug substance patent conflict

On a summary judgement filed by Celltrion over the Remicade’s substance patent(U.S. Patent No. 6,284,471, hereinafter referring to ‘471 substance patent’), the United States District Court for the District of Massachusetts has issued a ruling that the ‘471 substance patent’ is invalid on the 17^th(local time).

Although Janssen applied for the infringement lawsuit arguing the Celltrion’s biosim...